Novolog patent expiration?

“Novolog” (insulin aspart) is an older biologic/insulin product. Because insulin products can have different patent types (device/format, manufacturing processes, method-of-use, exclusivity), there isn’t one single “patent expiration date” that applies universally—expiration depends on the specific NDA/BLA, jurisdiction (US vs EU), and what exact patent you mean.

In the US (typical practical answer)

• Generic or biosimilar competition: In the US, insulin aspart is already available in follow-on products (e.g., biosimilar/authorized alternatives and “insulin aspart” follow-ons), meaning the original exclusivity/patent barriers are largely long over.
• What this usually means for “Novolog patent expiration”: the ability to market competition is already in place; exact patent expirations are usually not what consumers/pharmacies experience today—availability is driven by whether there are approved follow-on versions and interchangeability/labeling.

If you want the exact expiration date(s)

Tell me one of the following and I’ll narrow it down precisely:

1. Country (US, EU, UK, etc.)
2. Do you mean Novolog FlexPen/pen, vials, or insulin aspart overall?
3. Are you asking about original Novolog patents (insulin aspart) or specific “device” patents (injection pen technology)?

If you reply with the country + product format, I can help you identify the relevant patent(s)/exclusivity ending dates and how they affect what’s on the market.